We’ve been getting a lot of buzz around AcutaRex™ . Here is a short overview of this amazing product.
AcutaRex™
- utilizes a FDA 510(k) Acute Wound Care technology that expedites the wound site healing process by approximately 40%.
- is in a gel form and applied to topical wounds and surgical incisions.
- base product technology has been sold in the chronic wound market, but not the Acute market. Two new patents will be filed with the United States Patent and Trademark Office within 4 months that will exponentially increase the efficacy of the product .
- Total historical investment into current technology entity is approximately $145 million
- Current conservative replacement of expanded entity as of 2017 is estimated between $400 to $500 million in addition to 5-6 years for FDA regulatory approval.
